Integra LifeSciences Holdings Corporation’s (IART) growth in the third quarter is driven by sales growth within its Codman Specialty Surgical (“CSS”) arm despite ongoing supply challenges and temporary shipping holds. The company’s strong focus on portfolio optimization is encouraging. Meanwhile, headwinds such as a dull macro environment and weak liquidity position pose concerns for Integra’s operations.In the past year, this Zacks Rank #3 (Hold) company’s shares have lost 39.1% against the industry’s 14.7 ...

Integra LifeSciences Holding Corporation (IART) has announced the publication of a new economic study assessing the budget impact of switching treatment from fibrin glue to DuraSeal Polyethylene Glycol (“PEG”) hydrogel in five major European countries. The findings show an average cost savings of €419 to €1,279 per patient, with a consistent cost reduction averaging around 22% per procedure across Belgium, France, Germany and the United Kingdom, and 15% in Italy.The study, “PEG hydrogel sealant versus fibri ...

PRINCETON, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced the publication of a new economic study, “PEG hydrogel sealant versus fibrin glue in posterior fossa surgery: An economic comparison across five European countries.”1 The purpose of this evaluation was to assess the budget-impact of switching patient treatment from fibrin glue to DuraSeal Polyethylene Glycol (PEG) hydrogel in five major Eur ...

Integra LifeSciences Holdings Corporation (IART) delivered adjusted earnings per share (EPS) of 41 cents for the third quarter of 2024, a 46.1% plunge year over year. The metric, however, surpassed the Zacks Consensus Estimate by 5.1%.The adjustment excludes the impact of certain non-recurring charges like structural optimization charges, the Boston recall/Braintree transition and EU Medical Device Regulation charges among others.GAAP loss per share in the third quarter was 14 cents against GAAP EPS of 24 c ...

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Q3 2024 Earnings Call Transcript November 4, 2024 8:30 AM ET Company Participants Chris Ward - IR Stuart Essig - Executive Chairman Jan De Witte - President and CEO Lea Knight - CFO Conference Call Participants Steven Lichtman - Oppenheimer Vik Chopra - Wells Fargo Ryan Zimmerman - BTIG Kristen Stewart - C.L. King Robbie Marcus - JPMorgan Matt Taylor - Jefferies Richard Newitter - Truist Securities Craig Bijou - Bank of America Securities Joanne Wuensc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-26224 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) | --- | --- | |------ ...

INTEGRA _ Q3 2024 Earnings Presentation November 4, 2024 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this presentation. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. Some of these forward-looking statements may contain words like "will," " ...

Integra LifeSciences (IART) came out with quarterly earnings of $0.41 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.76 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 5.13%. A quarter ago, it was expected that this medical device maker would post earnings of $0.62 per share when it actually produced earnings of $0.63, delivering a surprise of 1.61%.Over the last four quarte ...

News Release Integra LifeSciences Reports Third Quarter 2024 Financial Results PRINCETON, N.J., November 4, 2024 - Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2024. Third Quarter 2024 Highlights • Third quarter revenues of $380.8 million decreased 0.4% on a reported basis and 8.6% on an organic basis compared to the prior year. Revenue decreased 10.3% on an organic basis exc ...

PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2024. Third Quarter 2024 Highlights Third quarter revenues of $380.8 million decreased 0.4% on a reported basis and 8.6% on an organic basis compared to the prior year. Revenue decreased 10.3% on an organic basis excluding Boston.Third quarter GAAP earnings per diluted share of $(0 ...